Literature DB >> 10766840

Ubiquitination of free cyclin D1 is independent of phosphorylation on threonine 286.

D Germain1, A Russell, A Thompson, J Hendley.   

Abstract

Cyclin D1 binds and regulates the activity of cyclin-dependent kinases (CDKs) 4 and 6. Phosphorylation of the retinoblastoma protein by cyclin D1.CDK4/6 complexes during the G(1) phase of the cell cycle promotes entry into S phase. Cyclin D1 protein is ubiquitinated and degraded by the 26 S proteasome. Previous studies have demonstrated that cyclin D1 ubiquitination is dependent on its phosphorylation by glycogen synthase kinase 3beta (GSK-3beta) on threonine 286 and that this phosphorylation event is greatly enhanced by binding to CDK4 (Diehl, J. A., Cheng, M. G., Roussel, M. F., and Sherr, C. J. (1998) Genes Dev. 12, 3499-3511). We now report an additional pathway for the ubiquitination of free cyclin D1 (unbound to CDKs). We show that, when unbound to CDK4, a cyclin D1-T286A mutant is ubiquitinated. Further, we show that a mutant of cyclin D1 that cannot bind to CDK4 (cyclin D1-KE) is also ubiquitinated in vivo. Our results demonstrate that free cyclin D1 is ubiquitinated independently of its phosphorylation on threonine 286 by GSK-3beta, suggesting that, as has been shown for cyclin E, distinct pathways of ubiquitination lead to the degradation of free and CDK-bound cyclin D1. The pathway responsible for ubiquitination of free cyclin D1 may be important in limiting the effects of cyclin D1 overexpression in a variety of cancers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10766840     DOI: 10.1074/jbc.275.16.12074

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

Review 1.  Cell cycle control mechanisms in B-1 and B-2 lymphoid subsets.

Authors:  Michael J Piatelli; Debra Tanguay; Thomas L Rothstein; Thomas C Chiles
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines.

Authors:  John P Alao; Simon C Gamble; Alexandra V Stavropoulou; Karen M Pomeranz; Eric W-F Lam; R Charles Coombes; David M Vigushin
Journal:  Mol Cancer       Date:  2006-02-17       Impact factor: 27.401

Review 3.  Regulation of chemoresistance via alternative messenger RNA splicing.

Authors:  Scott T Eblen
Journal:  Biochem Pharmacol       Date:  2012-01-08       Impact factor: 5.858

Review 4.  Advances in the understanding of mechanisms and therapeutic use of bortezomib.

Authors:  Taskeen Mujtaba; Q Ping Dou
Journal:  Discov Med       Date:  2011-12       Impact factor: 2.970

5.  P27Kip1 and p21Cip1 are not required for the formation of active D cyclin-cdk4 complexes.

Authors:  Tapan K Bagui; Subhra Mohapatra; Eric Haura; W J Pledger
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

6.  Impaired nuclear export of tumor-derived c-terminal truncated cyclin D1 mutant in ESCC cancer.

Authors:  Meili Hao; Xiangmei Chen; Ting Zhang; Tao Shen; Qing Xie; Xiujuan Xing; Hongxi Gu; Fengmin Lu
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

7.  Genomic organization and evolutionary conservation of plant D-type cyclins.

Authors:  Margit Menges; Giulio Pavesi; Piero Morandini; Laszlo Bögre; James A H Murray
Journal:  Plant Physiol       Date:  2007-10-19       Impact factor: 8.340

8.  PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1.

Authors:  Aurelian Radu; Valerie Neubauer; Tsuyoshi Akagi; Hidesaburo Hanafusa; Maria-Magdalena Georgescu
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

9.  Cyclin D2 protein stability is regulated in pancreatic beta-cells.

Authors:  Lu Mei He; Daniel J Sartori; Monica Teta; Lynn M Opare-Addo; Matthew M Rankin; Simon Y Long; J Alan Diehl; Jake A Kushner
Journal:  Mol Endocrinol       Date:  2009-07-23

10.  Lysine 269 is essential for cyclin D1 ubiquitylation by the SCF(Fbx4/alphaB-crystallin) ligase and subsequent proteasome-dependent degradation.

Authors:  O Barbash; E Egan; L L Pontano; J Kosak; J A Diehl
Journal:  Oncogene       Date:  2009-12-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.